Clinical Trial Update: UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating UV1 vaccination in combination with nivolumab and ipilimumab for malignant melanoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• UV1
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Ultimovacs ASA | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2025-01-14